Compare AbbVie Inc (ABBV) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Altria Group Inc — how do they compare? AbbVie Inc trades at $253.79 (market cap $449.91B), while Altria Group Inc trades at $73.48 (market cap $121.84B). The key difference: AbbVie Inc is far larger — about 3.7× Altria Group Inc's market cap, and Altria Group Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals.
| ABBV | MO | |
|---|---|---|
Market Cap | $449.91B | $121.84B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $74.55 |
52-Week Low | $184.85 | $54.72 |
Enterprise Value | $513.38B | $142.91B |
Dividend Yield | 2.72% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
MO trades at $72.96, up 0.34% today, with a bullish technical signal from moving averages and a neutral RSI near 60. The stock shows strong profitability with a 39.52% net margin and consistent cash flow, though revenue has been flat near $20.1B. Analysts are largely positive, with 62% recommending Buy and a consensus target of $70.75. Recent news highlights its appeal as a dividend king for income investors, with a $1.06 dividend paid in July 2026.
Outlook: MO offers stable income with high margins and dividend reliability, but faces risks from debt levels and regulatory pressures. The stock is near analyst targets, suggesting limited upside, yet remains a defensive hold for yield-seeking portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
